Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2020
Woman denied cancer drug on NHS which could extend her life because of where she lives
22 January 2020 - Ann, 64, can't get the drug she needs to survive because it's not available on the NHS ...
Posted by Michael Wonder on 22 Jan 2020
NHS patients denied new lung cancer drug after another NICE deadlock
22 January 2020 - Certain untreated lung cancer patients on England’s NHS will have to make do with older drugs ...
Posted by Michael Wonder on 22 Jan 2020
EU group calls for 'targeted actions' to mitigate impact of Brexit
22 January 2020 - Committee wants to ensure safe supply of drugs and medical devices. ...
Posted by Michael Wonder on 22 Jan 2020
NICE rejects Janssen’s Stelara on cost efficiency grounds
22 January 2020 - NICE has released a draft guidance not recommending Janssen’s Stelara (ustekinumab) for moderately to severely active ...
Posted by Michael Wonder on 21 Jan 2020
Achieving cost savings with biosimilars will require new strategies, authors say
20 January 2020 - Improving access to fairly priced, quality-assured generics and biosimilars is essential to realizing the potential public ...
Posted by Michael Wonder on 20 Jan 2020
After 20 years of using economic evaluation, should NICE be considered a methods innovator?
13 January 2020 - NICE is only one of several organisations internationally that uses economic evaluation as part of decision ...
Posted by Michael Wonder on 17 Jan 2020
Use of patient preference studies in HTA decision making: a NICE perspective
16 January 2020 - Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee ...
Posted by Michael Wonder on 17 Jan 2020
NICE encourages further data collection on ‘game changing’ histology independent cancer drugs
17 January 2020 - Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t ...
Posted by Michael Wonder on 16 Jan 2020
NICE ‘OK’ for Lynparza
16 January 2020 - NICE has recommended MSD and AstraZeneca’s Lynparza (olaparib) tablets, for adults who have relapsed platinum-sensitive ovarian, ...
Posted by Michael Wonder on 16 Jan 2020
Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund
15 January 2020 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...
Posted by Michael Wonder on 15 Jan 2020
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata
15 January 2020 - Cost-effectiveness watchdog issues a round of draft and final guidance. ...
Posted by Michael Wonder on 15 Jan 2020
NICE rejects Keytruda, asks for more information
15 January 2020 - NICE has published a new draft guidance not recommending MSD’s cancer blockbuster Keytruda (pembrolizumab) for untreated ...
Posted by Michael Wonder on 13 Jan 2020
Novartis strikes deal with UK to provide cholesterol drug to high-risk patients
13 January 2020 - Pharmaceutical giant Novartis reached a deal with the U.K. to provide its late-stage cholesterol drug, inclisiran, to ...
Posted by Michael Wonder on 12 Jan 2020
The Tories must learn from the Orkambi victory and keep drug-pricing off the table
12 January 2020 - To match its rhetoric on the NHS, the government has to legally commit to preventing drug-pricing being ...
Posted by Michael Wonder on 07 Jan 2020
As Brexit nears, fears of an NHS sell-out resurface
6 January 2020 - In the lead up to December’s general election in Britain one of the main campaign issues ...